西妥昔单抗对食管鳞状细胞癌患者的近期疗效及CEA、SCC、CA50、Caveolin-1表达的影响

Effect of Cetuximab on the Expression of CEA,SCC,CA50 and Caveolin-1 in Patients with Esophageal Squamous Cell Carcinoma

目的:探讨西妥昔单抗对食管鳞状细胞癌患者疗效及肿瘤标志物、Caveolin-1表达的影响。方法:选取2017年3月-2019年3月佳木斯市中心医院收治的104例食管鳞状细胞癌患者,按照随机数字表法将其分为观察组和对照组,每组52例。对照组给予顺铂+氟尿嘧啶化疗方案治疗,观察组采用西妥昔单抗联合顺铂+氟尿嘧啶化疗方案治疗。比较两组临床疗效、Caveolin-1阳性表达率、血清肿瘤标志物水平[癌胚抗原(CEA)、鳞状细胞癌相关抗原(SCC)、糖链抗原50(CA50)]、生存期指标、不良反应发生情况。结果:观察组失访3例、未严格执行化疗方案2例,对照组失访2例、自愿退出研究2例,剔除本研究。治疗后,观察组客观缓解率(ORR)、疾病控制率(DCR)分别为44.68%(21/47)、63.83%(30/47),均高于对照组的25.00%(12/48)、41.67%(20/48),差异均有统计学意义(P<0.05)。治疗后,两组CEA、SCC、CA50水平均低于治疗前,且观察组均低于对照组,差异均有统计学意义(P<0.05)。第1、2、3个疗程后,观察组Caveolin-1阳性表达率均低于对照组,差异均有统计学意义(P<0.05)。观察组的无进展生存期(PFS)、总生存期(OS)均长于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:西妥昔单抗联合DF化疗方案对食管鳞状细胞癌患者治疗效果显著,能够提升患者的疾病控制率和客观缓解率,降低肿瘤标志物水平,抑制Caveolin-1的阳性表达,延长患者的生命周期,治疗安全性良好。

Objective:To investigate the effect of Cetuximab on the expression of tumor markers and Caveolin-1 in patients with esophageal squamous cell carcinoma.Method:A total of 104 patients with esophageal squamous cell carcinoma admitted to Jiamusi Central Hospital from March 2017 to March 2019 were selected,they were divided into observation group and control group according to random number table method,52 cases in each group.The control group was treated with Cisplatin + Fluorouracil chemotherapy,while the observation group was treated with Cetuximab combined with Cisplatin + Fluorouracil chemotherapy.The clinical efficacy,positive expression rate of Caveolin-1,serum tumor markers[carcinoembryonic antigen (CEA),squamous cell carcinoma associated antigen (SCC),sugar chain antigen 50 (CA50)],survival indices and incidence of adverse reactions were compared between two groups.Result:In the observation group,3 patients were lost to follow-up and 2 patients did not strictly follow the chemotherapy regimen,while in the control group,2 patients were lost to follow-up and 2 patients voluntarily withdrew from the study,they were eliminated.After treatment,the objective response rate (ORR) and disease control rate (DCR) of the observation group were 44.68% (21/47) and 63.83% (30/47),respectively,which were higher than 25.00% (12/48) and 41.67% (20/48) of the control group,the differences were statistically significant (P<0.05).After treatment,CEA,SCC and CA50 levels of both groups were lower than those before treatment,and those of the observation group were lower than those of the control group,the differences were statistically significant (P<0.05).After the first,second and third course,the positive expression rates of Caveolin-1 of the observation group were lower than those of the control group,the differences were statistically significant (P<0.05).The progression-free survival (PFS) and overall survival (OS) of the observation group were longer than those of the control group,the differences were statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:Cetuximab combined with Cisplatin + Fluorouracil chemotherapy is effective in the treatment of patients with esophageal squamous cell carcinoma,which can improve the disease control rate and objective remission rate,reduce the level of tumor markers,inhibit the positive expression of Caveolin-1,prolong the life cycle of patients with good safety.